{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T12:04:12Z","timestamp":1753877052857,"version":"3.41.2"},"reference-count":42,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T00:00:00Z","timestamp":1748304000000},"content-version":"vor","delay-in-days":29,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Chronic hepatitis E virus (HEV) infection, which primarily affects the immunocompromised, can rapidly progress to liver fibrosis and cirrhosis if untreated. However, current therapeutic options are extremely limited and have significant adverse effects. Over the past decade, virus-specific T-cell therapy has shown promise as an alternative safe and effective treatment strategy for other refractory viral infections such as cytomegalovirus, adenovirus, and polyomavirus infections in hematopoietic stem cell and solid organ transplant recipients. Given the key role of T lymphocytes in the control of HEV replication and the fact that HEV-specific T-cell responses are typically diminished in immunosuppressed patients with persistent HEV infection, adoptive immunotherapy with HEV-specific T cells could serve as a novel addition to the HEV treatment repertoire, which is in dire need of expansion.<\/jats:p>","DOI":"10.1093\/ofid\/ofaf231","type":"journal-article","created":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T08:57:51Z","timestamp":1748336271000},"source":"Crossref","is-referenced-by-count":0,"title":["Can Adoptive Immunotherapy With Hepatitis E Virus (HEV)\u2013Specific T Cells Address the Unmet Need in Refractory Chronic HEV Infection?"],"prefix":"10.1093","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7652-4236","authenticated-orcid":false,"given":"Temi","family":"Lampejo","sequence":"first","affiliation":[{"name":"Faculty of Medicine and Life Sciences, King's College London , London ,","place":["UK"]},{"name":"Department of Infection Sciences, King's College Hospital , London ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,5,27]]},"reference":[{"key":"2025052704574931100_ofaf231-B1","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1016\/S0140-6736(11)61849-7","article-title":"Hepatitis E","volume":"379","author":"Kamar","year":"2012","journal-title":"Lancet"},{"author":"World Health Organization.","key":"2025052704574931100_ofaf231-B2"},{"key":"2025052704574931100_ofaf231-B3","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.3390\/cells10092281","article-title":"Hepatitis E virus infection\u2014immune responses to an underestimated global threat","volume":"10","author":"Kupke","year":"2021","journal-title":"Cells"},{"key":"2025052704574931100_ofaf231-B4","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.jhep.2019.07.018","article-title":"Paving the way for T cell-based immunotherapies in chronic hepatitis E","volume":"71","author":"Neumann-Haefelin","year":"2019","journal-title":"J Hepatol"},{"key":"2025052704574931100_ofaf231-B5","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1093\/infdis\/jiy504","article-title":"Absence of persistent hepatitis E virus infection in antibody-deficient patients is associated with transfer of antigen-neutralizing antibodies from immunoglobulin products","volume":"219","author":"Ankcorn","year":"2019","journal-title":"J Infect Dis"},{"key":"2025052704574931100_ofaf231-B6","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.jhep.2019.04.008","article-title":"Convalescent plasma therapy for persistent hepatitis E virus infection","volume":"71","author":"Ankcorn","year":"2019","journal-title":"J Hepatol"},{"key":"2025052704574931100_ofaf231-B7","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.jhep.2022.05.006","article-title":"Chronic hepatitis E: advancing research and patient care","volume":"77","author":"Ma","year":"2022","journal-title":"J Hepatol"},{"key":"2025052704574931100_ofaf231-B8","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/j.jhep.2022.05.019","article-title":"Mechanisms of CD8+ T-cell failure in chronic hepatitis E virus infection","volume":"77","author":"Kemming","year":"2022","journal-title":"J Hepatol"},{"key":"2025052704574931100_ofaf231-B9","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1056\/NEJMoa1215246","article-title":"Ribavirin for chronic hepatitis E virus infection in transplant recipients","volume":"370","author":"Kamar","year":"2014","journal-title":"N Engl J Med"},{"key":"2025052704574931100_ofaf231-B10","doi-asserted-by":"crossref","first-page":"788.e1","DOI":"10.1016\/j.jtct.2022.08.020","article-title":"Hepatitis E virus infection in cancer patients","volume":"28","author":"Chiu","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"2025052704574931100_ofaf231-B11","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1093\/infdis\/jiu032","article-title":"Hepatitis E virus reinfections in solid-organ-transplant recipients can evolve into chronic infections","volume":"209","author":"Abravanel","year":"2014","journal-title":"J Infect Dis"},{"key":"2025052704574931100_ofaf231-B12","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1136\/gut.2008.165571","article-title":"Reactivation of hepatitis E infection in a patient with acute lymphoblastic leukaemia after allogeneic stem cell transplantation","volume":"58","author":"Le Coutre","year":"2009","journal-title":"Gut"},{"key":"2025052704574931100_ofaf231-B13","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.3748\/wjg.v27.i12.1240","article-title":"Hepatitis E in solid organ transplant recipients: a systematic review and meta-analysis","volume":"27","author":"Hansrivijit","year":"2021","journal-title":"World J Gastroenterol"},{"key":"2025052704574931100_ofaf231-B14","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1053\/j.gastro.2011.02.050","article-title":"Factors associated with chronic hepatitis in patients with hepatitis E virus infection who have received solid organ transplants","volume":"140","author":"Kamar","year":"2011","journal-title":"Gastroenterology"},{"key":"2025052704574931100_ofaf231-B15","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.jhep.2019.04.022","article-title":"The burden of hepatitis E among patients with haematological malignancies: a retrospective European cohort study","volume":"71","author":"Von Felden","year":"2019","journal-title":"J Hepatol"},{"key":"2025052704574931100_ofaf231-B16","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.4254\/wjh.v7.i19.2194","article-title":"Chronic hepatitis E: a brief review","volume":"7","author":"Murali","year":"2015","journal-title":"World J Hepatol"},{"key":"2025052704574931100_ofaf231-B17","doi-asserted-by":"crossref","first-page":"e13514","DOI":"10.1111\/ctr.13514","article-title":"Viral hepatitis: guidelines by the American Society of Transplantation Infectious Disease Community of Practice","volume":"33","author":"Te","year":"2019","journal-title":"Clin Transplant"},{"key":"2025052704574931100_ofaf231-B18","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1093\/cid\/ciz953","article-title":"Ribavirin for hepatitis E virus infection after organ transplantation: a large European retrospective multicenter study","volume":"71","author":"Kamar","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2025052704574931100_ofaf231-B19","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1111\/jvh.12403","article-title":"Antiviral therapy in chronic hepatitis E: a systematic review","volume":"22","author":"Peters van Ton","year":"2015","journal-title":"J Viral Hepat"},{"key":"2025052704574931100_ofaf231-B20","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/j.jceh.2022.02.003","article-title":"Sofosbuvir in the treatment of hepatitis E virus infection: a review of in vitro and in vivo evidence","volume":"12","author":"Lampejo","year":"2022","journal-title":"J Clin Exp Hepatol"},{"key":"2025052704574931100_ofaf231-B21","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1002\/hep.30428","article-title":"Sofosbuvir and ribavirin eradication of refractory hepatitis E in an immunosuppressed kidney transplant recipient","volume":"69","author":"Drinane","year":"2019","journal-title":"Hepatology"},{"key":"2025052704574931100_ofaf231-B22","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1097\/HEP.0000000000000514","article-title":"Emergence of resistance-associated variants during sofosbuvir treatment in chronically infected hepatitis E patients","volume":"78","author":"G\u00f6mer","year":"2023","journal-title":"Hepatology"},{"key":"2025052704574931100_ofaf231-B23","doi-asserted-by":"crossref","first-page":"485","DOI":"10.3390\/v11060485","article-title":"Hepatitis E virus drug development","volume":"11","author":"Kinast","year":"2019","journal-title":"Viruses"},{"key":"2025052704574931100_ofaf231-B24","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.antiviral.2018.07.010","article-title":"The natural compound silvestrol inhibits hepatitis E virus (HEV) replication in vitro and in vivo","volume":"157","author":"Todt","year":"2018","journal-title":"Antiviral Res"},{"key":"2025052704574931100_ofaf231-B25","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1016\/j.jhep.2018.03.005","article-title":"EASL clinical practice guidelines on hepatitis E virus infection","volume":"68","author":"Dalton","year":"2018","journal-title":"J Hepatol"},{"key":"2025052704574931100_ofaf231-B26","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.dld.2020.05.044","article-title":"Ribavirin long-term treatment for chronic hepatitis E virus infection in a liver transplant recipient","volume":"52","author":"Casper","year":"2020","journal-title":"Dig Liver Dis"},{"issue":"Suppl 1","key":"2025052704574931100_ofaf231-B27","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1093\/jpids\/piad077","article-title":"Virus-specific T cells for the treatment of systemic infections following allogeneic hematopoietic cell and solid organ transplantation","volume":"13","author":"Green","year":"2024","journal-title":"J Pediatric Infect Dis Soc"},{"key":"2025052704574931100_ofaf231-B28","doi-asserted-by":"crossref","first-page":"e20191663","DOI":"10.1084\/jem.20191663","article-title":"Challenges of CAR- and TCR-T cell-based therapy for chronic infections","volume":"217","author":"Bertoletti","year":"2020","journal-title":"J Exp Med"},{"key":"2025052704574931100_ofaf231-B29","doi-asserted-by":"crossref","first-page":"10339","DOI":"10.1038\/s41467-024-54595-2","article-title":"Compassionate access to virus-specific T cells for adoptive immunotherapy over 15 years","volume":"15","author":"Neller","year":"2024","journal-title":"Nat Commun"},{"key":"2025052704574931100_ofaf231-B30","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1053\/j.gastro.2014.02.036","article-title":"Calcineurin inhibitors stimulate and mycophenolic acid inhibits replication of hepatitis E virus","volume":"146","author":"Wang","year":"2014","journal-title":"Gastroenterology"},{"key":"2025052704574931100_ofaf231-B31","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1097\/TP.0b013e3182a7fcf8","article-title":"Rapamycin enhances long-term hematopoietic reconstitution of ex vivo expanded mouse hematopoietic stem cells by inhibiting senescence","volume":"97","author":"Luo","year":"2014","journal-title":"Transplantation"},{"key":"2025052704574931100_ofaf231-B32","first-page":"5745","article-title":"Virus-specific T-cell therapy to treat BK polyomavirus infection in bone marrow and solid organ transplant recipients","volume":"4","author":"Nelson","year":"2020","journal-title":"Blood Adv"},{"issue":"Suppl 1","key":"2025052704574931100_ofaf231-B33","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1182\/blood-2022-169122","article-title":"Final clinical outcomes from a phase 2 trial of posoleucel, an off-the-shelf, multivirus-specific T-cell therapy, for the prevention of clinically significant viral infections post-HCT","volume":"140","author":"Dadwal","year":"2022","journal-title":"Blood"},{"key":"2025052704574931100_ofaf231-B34","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.bbmt.2007.02.004","article-title":"Ex vivo expansion and prophylactic infusion of CMV-pp65 peptide-specific cytotoxic T-lymphocytes following allogeneic hematopoietic stem cell transplantation","volume":"13","author":"Micklethwaite","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"key":"2025052704574931100_ofaf231-B35","doi-asserted-by":"crossref","first-page":"3745","DOI":"10.1182\/blood-2012-08-448977","article-title":"Donor-derived CMV-specific T cells reduce the requirement for CMV-directed pharmacotherapy after allogeneic stem cell transplantation","volume":"121","author":"Blyth","year":"2013","journal-title":"Blood"},{"key":"2025052704574931100_ofaf231-B36","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1038\/s41375-019-0600-z","article-title":"Generation and infusion of multi-antigen-specific T cells to prevent complications early after T-cell depleted allogeneic stem cell transplantation\u2014a phase I\/II study","volume":"34","author":"Roex","year":"2020","journal-title":"Leukemia"},{"key":"2025052704574931100_ofaf231-B37","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.1182\/bloodadvances.2021006309","article-title":"Scheduled administration of virus-specific T cells for viral prophylaxis after pediatric allogeneic stem cell transplant","volume":"6","author":"Rubinstein","year":"2022","journal-title":"Blood Adv"},{"key":"2025052704574931100_ofaf231-B38","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/hep.31662","article-title":"Immunosuppressive drug-resistant armored T-cell receptor T cells for immune therapy of HCC in liver transplant patients","volume":"74","author":"Hafezi","year":"2021","journal-title":"Hepatology"},{"key":"2025052704574931100_ofaf231-B39","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1038\/s41423-023-01080-3","article-title":"Engineering immunosuppressive drug-resistant armored (IDRA) SARS-CoV-2 T cells for cell therapy","volume":"20","author":"Chen","year":"2023","journal-title":"Cell Mol Immunol"},{"key":"2025052704574931100_ofaf231-B40","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1007\/s12072-021-10250-2","article-title":"Immunotherapy of HBV-related advanced hepatocellular carcinoma with short-term HBV-specific TCR expressed T cells: results of dose escalation, phase I trial","volume":"15","author":"Meng","year":"2021","journal-title":"Hepatol Int"},{"key":"2025052704574931100_ofaf231-B41","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.jhep.2019.06.005","article-title":"Defining virus-specific CD8+ TCR repertoires for therapeutic regeneration of T cells against chronic hepatitis E","volume":"71","author":"Soon","year":"2019","journal-title":"J Hepatol"},{"key":"2025052704574931100_ofaf231-B42","doi-asserted-by":"crossref","first-page":"6027361","DOI":"10.1155\/2020\/6027361","article-title":"Th1\/Th2 cells and associated cytokines in acute hepatitis E and related acute liver failure","volume":"2020","author":"Wu","year":"2020","journal-title":"J Immunol Res"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/12\/5\/ofaf231\/63368260\/ofaf231.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/12\/5\/ofaf231\/63368260\/ofaf231.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T08:57:57Z","timestamp":1748336277000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofaf231\/8151278"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,28]]},"references-count":42,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,4,28]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofaf231","relation":{},"ISSN":["2328-8957"],"issn-type":[{"type":"electronic","value":"2328-8957"}],"subject":[],"published-other":{"date-parts":[[2025,5]]},"published":{"date-parts":[[2025,4,28]]},"article-number":"ofaf231"}}